DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

CDMO Samsung Biologics expanded its collaboration with LigaChem Biosciences (LCB) to provide antibody-drug conjugate (ADC) services. Samsung will support a series of LigaChem’s ADC programs at Samsung ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based ...

Samsung Biologics signed a partnership deal with LegoChem Biosciences focused on the development and production of antibody-drug conjugates (ADCs). Although financial details of the deal weren’t ...

Gilead is making a move in the hunt for antibody-drug conjugates (ADCs) that target solid tumors by tapping Tubulis, a German biotech that specializes in the molecules, to collaboratively discover and ...

The collaboration achieves synergy across the entire value chain from AI-driven design and antibody development to payload-linker chemical synthesis and clinical development, establishing a complete, ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...

TAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, ...

ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the two announcements, the company’s stock, ...